Abstract:
A diverse endocrine condition, polycystic ovarian syndrome (PCOS) is characterized by ovarian cysts, anovulation, and endocrine variance in women. According to estimates from the World Health Organization (WHO), PCOS affects more than 116 million women globally (3.4%). Depending on the criterion used, 6%-25% of reproductive-aged women are affected with polycystic ovary syndrome, which is now a well-known disorder. Genetics, neuroendocrine, lifestyle/environment, and obesity are among the risk factors that predispose people to PCOS. The pathophysiology of PCOS primarily focuses on hormonal disruption, insulin resistance, and hyperandrogenism, which cause poor folliculogenesis and increase the risk of related comorbidities such as endometrial cancer and type II diabetes. According to a study of the available information from throughout the world, the prevalence of PCOS may vary from 4% to 18% in general populations, but it may be as high as 26% in particular groups. This study gives a short summary of the clinical symptoms, risks, and pathophysiological treatments for anovulation, infertility, and PCOS.
